Group 1 - WuXi Biologics plans to spin off its bioconjugate drug CRDMO service company, WuXi AppTec, for a listing on the Hong Kong Stock Exchange, amid challenges in market capitalization and future performance [1] - As of July 11, 2023, WuXi Biologics' stock price has decreased by 50.9% from its peak of 77.4 HKD per share, resulting in a total market value loss exceeding 100 billion HKD [1] - The competitive landscape in the CXO sector is intensifying, with companies like Samsung Biologics securing significant contracts, such as a 400 million USD deal with Pfizer for biosimilar production [1] Group 2 - The global ADC outsourcing service market is projected to grow significantly, reaching 11 billion USD by 2030, with a compound annual growth rate of 28.4% from 2022 to 2030 [2] - The spin-off of WuXi AppTec is seen as a strategic move to enhance operational efficiency and capitalize on the growth opportunities in the ADC and bioconjugate markets [2] - The uncertainty remains regarding whether the spin-off will positively impact WuXi Biologics' performance and stock price [2]
药明生物分拆子公司上市能否逆转市值缩水？